Alan W. Heldman, M.D.
- American Board of Internal Med-Cardiovascular Disease
- Internal Medicine
- Interventional Cardiology - Internal Medicine
- Cardiovascular Disease - Internal Medicine
- Director of Interventional Cardiology
- Interventional Cardiologist
- Medical Director, Heart Valve Program
- Professor of Medicine, Cardiovacular Division
Complex and high-risk coronary intervention
Hypertrophic cardiomyopathy, including treatment with alcohol septal ablation
Techniques to reduce or eliminate complications from interventional procedures
Stem cell therapy for myocardial infarction and heart failure
Non-surgical treatments for structural heart disease and valvular heart disease
Stem Cell Therapy for Myocardial Infarction and Heart Failure
Catheter Delivery of Stem Cells to the Heart
Non-surgical treatment of structural heart disease and valvular heart disease
Coronary Stent Design and Drug-Eluting Stents
Vein Graft Intervention and Protection Devices
Fellow, Society for Cardiovascular Angiography and Interventions
Johns Hopkins University
Johns Hopkins University
Johns Hopkins University
1988 M.D., with honors
University of Alabama at Birmingham
1984 A.B., cum laude
- Heldman AW, Wu KC, Abraham TP, Cameron DE. Myectomy or alcohol septal ablation: Surgery and percutaneous intervention go another round. J Am Coll Cardiol. 2007 Jan 23;49(3):358-60.
- Atiemo A, Conte JV, Heldman AW. Resuscitation and Recovery from Acute Right Ventricular Failure Using a Percutaneous Right Ventricular Assist Device. Catheterization and Cardiovascular Interventions 2006 Jun 8;68(1):78-82.
- Gershlick A, De Scheerder I, Chevalier B, Camenzind E, Vrints C, Reifart N, Missault L, Goy J-J, Stephens-Lloyd A, Brinker J, Raizner E, Urban P, Heldman AW. Inhibition of Restenosis with a Paclitaxel-eluting polymer-free Coronary Stent: The European evaLUation of pacliTaxel Eluting Stent (ELUTES) Trial. Circulation. 2004;109:487-493.
- Lardizabal JA, Macon CJ, O'Neill BP, Singh V, Martinez CA, Alfonso C, Cohen MG, Williams DB, O'Neill WW, Heldman AW. Clinical outcomes with on-label and off-label use of the transcatheter heart valve in the United States. Catheter Cardiovasc Interv. 2014 Jul 1;84(1):124-8. doi: 10.1002/ccd.25489. Epub 2014 Apr 1. PubMed PMID: 24659187.
- Suncion VY, Ghersin E, Fishman JE, Zambrano JP, Karantalis V, Mandel N, Nelson KH, Gerstenblith G, DiFede Velazquez DL, Breton E, Sitammagari K, Schulman IH, Taldone SN, Williams AR, Sanina C, Johnston PV, Brinker J, Altman P, Mushtaq M, Trachtenberg B, Mendizabal AM, Tracy M, Da Silva J, McNiece IK, Lardo AC, George RT, Hare JM, Heldman AW. Does transendocardial injection of mesenchymal stem cells improve myocardial function locally or globally?: An analysis from the Percutaneous Stem Cell Inj
- Does transendocardial injection of mesenchymal stem cells improve myocardial function locally or globally?: An analysis from the Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis (POSEIDON) randomized trial. Circ Res. 2014 Apr 11;114(8):1292-301.
- Transendocardial mesenchymal stem cells and mononuclear bone marrow cells for ischemic cardiomyopathy: the TAC-HFT randomized trial. Heldman AW, DiFede DL, Fishman JE, et al. JAMA. 2014 Jan 1;311(1):62-73
Areas of Specialization
- Stem cell therapy for myocardial infarction and heart failure
- Minimally invasive transcatheter aortic valve replacement (TAVR) and other valvular and structural heart interventions
- Complex and high-risk coronary intervention, including treatment and prevention of coronary stent restenosis
- Rotational Ablation, Excimer Laser Angioplasty, and other coronary treatment modalities
- Hypertrophic cardiomyopathy, including medical treatment, surgical planning, and treatment with alcohol septal ablation
- Techniques to reduce or eliminate complications from interventional procedures, including transradial catheterization and image-guided vascular access and repair.
Alan W. Heldman, M.D., is Professor and Director of interventional cardiology at the University of Miami Miller School of Medicine, where he holds the Elaine and Sydney Sussman Chair in Interventional Cardiology. Educated at Harvard College, University of Alabama at Birmingham School of Medicine, and trained in internal medicine, cardiovascular disease, and interventional cardiology all at Johns Hopkins University, Dr. Heldman spent 12 years on the faculty in cardiology at Johns Hopkins, where he was director of Interventional Cardiology Innovation & Research and a high volume interventional operator.
Dr. Heldman has performed hundreds of transcatheter aortic valve replacement procedures since 2008 and is the most experienced cardiologist in Florida with this minimally invasive treatment for aortic stenosis. He has also performed hundreds of transcatheter stem cell injection procedures for the treatment of variety of cardiovascular disorders. He coordinates a multi-disciplinary clinical effort for the evaluation and care of patients with hypertrophic cardiomyopathy.